Clinical trial
Clinical Protocol Bortezomib Consolidation in Patients With Myeloma Following Treatment With High-dose Melphalan and Autologous Stem Cell Support. A Randomised NMSG Trial (15/05)
NCT00417911 is registered in ClinicalTrials.gov with Nordic Myeloma Study Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Protocol Bortezomib Consolidation in Patients With Myeloma Following Treatment With High-dose Melphalan and Autologous Stem Cell Support. A Randomised NMSG Trial (15/05)
- Lead sponsor
- Nordic Myeloma Study Group
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2005
- Completion date
- May 31, 2010
- Enrollment
- 400 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.